PGI2 restricts trained ILC2 responses in allergic inflammation
Pulmonary type 2 innate lymphoid cells (ILC2s) exhibit immune memory, termed "trained immunity," which enhances their activation following exposure to an independent protease-containing allergen. The role of prostaglandin I2 (PGI2), a cyclooxygenase (COX) pathway metabolite, in modulating these trained ILC2 responses remains unclear. PGI2 acts through its G protein-coupled receptor IP. We hypothesized that IP signaling inhibits ILC2 training. To test this hypothesis, we used a mouse ILC2 training model in which we challenged wild-type (WT) and IP knockout (KO) mice with Alternaria alternata extract (Alt) to induce ILC2 activation and training. After a 33-d resting period, ILC2 responses subsided to a homeostatic level. Mice were then intranasally challenged with papain to evaluate responses to an unrelated allergen. IP KO mice displayed significantly heightened ILC2 interleukin (IL)-13 expression and with concomitant increased eosinophilia in the lungs post-papain challenge compared with WT control mice. Notably, neither WT nor IP KO mice challenged with papain only, devoid of ILC2 training, exhibited lung type 2 responses. The augmented type 2 inflammation observed in IP KO mice following both Alt and papain challenges correlated with increased numbers and percentages of IL-13-producing ILC2s and greater mean fluorescence intensity of IL-13 compared with WT mice. Furthermore, RNA sequencing of sorted ILC2s from WT and IP KO mice following Alt-papain challenges revealed heightened activation of immune response pathways and mitochondrial respiratory pathways in IP-deficient ILC2s. These findings reveal an inhibitory role of PGI2 signaling in trained ILC2 responses, emphasizing its pivotal contribution to innate immune responses and allergic inflammation.
Authors
- Christian M. Warren
- Allison E. Norlander (ORCID: https://orcid.org/0000-0002-9357-485X)
- Mark Rusznak
- Weisong Zhou (ORCID: https://orcid.org/0000-0002-4419-2302)
- Shinji Toki (ORCID: https://orcid.org/0000-0003-4379-9118)
- Ginger L. Milne (ORCID: https://orcid.org/0000-0003-3890-151X)
- Masako Abney
- Daniel P. Cook (ORCID: https://orcid.org/0000-0002-1152-4454)
- Dawn C. Newcomb (ORCID: https://orcid.org/0000-0003-2592-9433)
- Katherine N. Gibson‐Corley (ORCID: https://orcid.org/0000-0002-1846-1580)
- R. Stokes Peebles (ORCID: https://orcid.org/0000-0002-1429-7875)
- Bradley W. Richmond (ORCID: https://orcid.org/0000-0001-6200-5235)
- Jian Zhang (ORCID: https://orcid.org/0000-0001-7217-0111)
- Christopher Thomas
Institutions
- University of Iowa (US)
- Vanderbilt University (US)
- VA Tennessee Valley Healthcare System (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1093/jimmun/vkaf088
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health